keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasys

keyword
https://www.readbyqxmd.com/read/28805939/molecular-and-cellular-discoveries-in-inflammatory-dermatoses
#1
REVIEW
V Soumelis
It was no earlier than 1986 that T helper (Th)1 and Th2 cells were described for the first time, opening the field of lymphocyte diversity and the investigation of the physiopathology of inflammatory diseases such as atopic dermatitis and psoriasis. Since that time, much research has been carried out showing a very complex communication network leading to inflammatory responses. Nowadays, understanding the cellular and molecular components of the inflammatory network and of the different crosstalks not only for groups of diseases but also for the individual patient is mandatory for developing and personalizing treatments...
September 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28805045/safety-and-efficacy-of-intravenous-golimumab-in-patients-with-active-psoriatic-arthritis-results-through-week-24-of-the-go-vibrant-study
#2
Arthur Kavanaugh, M Elaine Husni, Diane D Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H Leu, Elizabeth C Hsia
OBJECTIVE: Evaluate the safety and efficacy of intravenous golimumab in psoriatic arthritis (PsA). METHODS: In this Phase 3, randomized, double-blind, placebo-controlled trial, patients were randomized to intravenous placebo (n=239) or golimumab 2 mg/kg (n=241) at weeks 0, 4, 12, and 20. The primary endpoint was the proportion of patients with ≥20% improvement in ACR criteria (ACR20) at week14. Controlled secondary endpoints included change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI), proportions of patients with ACR50, ACR70, and ≥75% improvement in Psoriasis Area and Severity Index (PASI75) at week14, and change from baseline in total PsA-modified van der Heijde-Sharp (vdH-S) score at week24...
August 13, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28804988/patterns-of-systemic-treatment-for-psoriatic-arthritis-in-the-united-states-2004-2015
#3
Moa P Lee, Joyce Lii, Yinzhu Jin, Rishi J Desai, Daniel H Solomon, Joseph F Merola, Seoyoung C Kim
OBJECTIVE: To examine trends in use of systemic disease-modifying antirheumatic drugs (DMARD) among patients with psoriatic arthritis (PsA) in the U.S. METHODS: Using claims data (2004-2015) from a large U.S. commercial healthplan, we identified patients with PsA who initiated DMARDs. We examined baseline patient characteristics and initial treatment patterns. We then assessed changes in the DMARD regimen over the 12-month period after the 1(st) DMARD initiation date...
August 13, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28804689/the-role-of-the-skin-and-gut-microbiome-in-psoriatic-disease
#4
Di Yan, Naiem Issa, Ladan Afifi, Caleb Jeon, Hsin Wen Chang, Wilson Liao
PURPOSE: To understand the changes in the microbiome in psoriatic disease, we conducted a systematic review of studies comparing the skin and gut microbiota in psoriatic individuals and healthy controls. FINDINGS: Our review of studies pertaining to the cutaneous microbiome showed a trend towards an increased relative abundance of Streptococcus and a decreased level of Propionibacterium in psoriasis patients compared to controls. In the gut microbiome, the ratio of Firmicutes and Bacteroidetes was perturbed in psoriatic individuals compared to healthy controls...
June 2017: Current Dermatology Reports
https://www.readbyqxmd.com/read/28803785/vascular-endothelial-growth-factor-vegf-gene-polymorphisms-rs699947-rs833061-and-rs2010963-and-psoriatic-risk-in-south-indian-tamils
#5
Anjana Sudhesan, Medha Rajappa, Laxmisha Chandrashekar, P H Ananthanarayanan, D M Thappa, Santhosh Satheesh, Adithan Chandrasekaran
BACKGROUND: Psoriasis is a chronic inflammatory disease of the skin. Vascular endothelial growth factor (VEGF), a pro-angiogenic factor, is involved in the pathogenesis of psoriasis. Being highly polymorphic, several SNPs of VEGF have been reported to be associated with increased risk of psoriasis. OBJECTIVES: We determined the association of VEGF gene polymorphisms with risk of psoriasis in South Indian Tamils. METHODS: 300 cases of psoriasis and 300 controls were recruited in this case-control study...
August 10, 2017: Human Immunology
https://www.readbyqxmd.com/read/28803431/sb2-an-infliximab-biosimilar
#6
Yvette N Lamb, Lesley J Scott, Emma D Deeks
SB2 is a biosimilar of the reference anti-TNF-α antibody infliximab. In May 2015, it was approved in the EU for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis. It is also approved in these indications in several other countries, including Korea, the USA and Australia. Characterization of SB2 in preclinical studies showed that it is similar to reference infliximab...
August 12, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28801811/association-of-variably-expressed-kir3dl1-alleles-with-psoriatic-disease
#7
Jeffrey Berinstein, Remy Pollock, Fawnda Pellett, Arane Thavaneswaran, Vinod Chandran, Dafna D Gladman
The purpose of this study is to examine the genetic interaction of variably expressed killer cell immunoglobulin-like receptor (KIR) 3DL1 alleles with their cognate ligand, human leukocyte antigen (HLA)-Bw4, in susceptibility to psoriatic disease (PsD). A novel allelic typing system was developed to differentiate KIR3DL1 alleles (*High, *Low, *Null expression, and 3DS1), in PsD patients, including those with psoriatic arthritis (PsA) and cutaneous psoriasis without arthritis (PsC) and healthy controls. Frequencies of each KIR3DL1 allele, Bw4-80I and Bw4-80T, as well as the genetic interaction between the KIR3DL1 alleles and the Bw4 epitope were analyzed...
August 11, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28799796/immune-modulation-by-curcumin-the-role-of-interleukin-10
#8
Hamid Mollazadeh, Arrigo F G Cicero, Christopher N Blesso, Matteo Pirro, Muhammed Majeed, Amirhossein Sahebkar
Cytokines are small secreted proteins released by different types of cells with specific effects on cellular signaling and communication via binding to their receptors on the cell surface. IL-10 is known to be a pleiotropic and potent anti-inflammatory and immunosuppressive cytokine that is produced by both innate and adaptive immunity cells including dendritic cells, macrophages, mast cells, natural killer cells, eosinophils, neutrophils, B cells, CD8(+) T cells, and TH1, TH2, and TH17 and regulatory T cells...
August 11, 2017: Critical Reviews in Food Science and Nutrition
https://www.readbyqxmd.com/read/28797265/risk-and-predictors-of-psoriasis-in-patients-with-breast-cancer-a-swedish-population-based-cohort-study
#9
Haomin Yang, Judith S Brand, Jingmei Li, Jonas F Ludvigsson, Emilio Ugalde-Morales, Flaminia Chiesa, Per Hall, Kamila Czene
BACKGROUND: The risk of psoriasis in patients with breast cancer is largely unknown, as available evidence is limited to case findings. We systematically examined the incidence and risk factors of psoriasis in patients with breast cancer. METHODS: A Swedish nationwide cohort of 56,235 breast cancer patients (2001-2012) was compared to 280,854 matched reference individuals from the general population to estimate the incidence and hazard ratio (HR) of new-onset psoriasis...
August 11, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28797188/validation-of-psychometric-properties-and-development-of-response-criteria-for-the-psoriasis-symptoms-and-signs-diary-pssd-results-from-a-phase-iii-clinical-trial
#10
April Armstrong, Luis Puig, Richard Langley, Tsen Fang Tsai, Michael Song, Yasmine Wasfi, Jingzhi Jiang, Shu Li, Chenglong Han
PURPOSE: The Psoriasis Symptoms and Signs Diary (PSSD) is a patient-reported instrument that assesses severity of six psoriasis symptoms (itch, skin tightness, burning, stinging, and pain,) and five signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding). MATERIALS AND METHODS: PSSD symptoms and signs summary scores (0-100) were derived based on individual item scores (0-10 [absent-worst imaginable]). Using Psoriasis Area and Severity Index [PASI], Investigator's Global Assessment [IGA] and Dermatology Life Quality Index [DLQI]) data from the NAVIGATE trial of patients with moderate-to-severe psoriasis, analyses were conducted to further validate the PSSD (7-day recall version) and establish criteria for clinically meaningful improvements (CMIs)...
August 11, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28796913/patients-with-psoriasis-have-different-preferences-for-topical-therapy-highlighting-the-importance-of-individualized-treatment-approaches-randomized-phase-iiib-pso-insightful-study
#11
C-H Hong, K A Papp, K W Lophaven, P Skallerup, S Philipp
BACKGROUND: Poor adherence to topical therapy in psoriasis remains an issue; it is associated with poor clinical outcomes, reduced quality of life, and increased costs. Treatment-related factors leading to poor adherence include lack of efficacy, excessive time applying medication, and poor cosmetic characteristics (e.g. slow absorption, greasiness). OBJECTIVE: To assess the topical treatment attributes that influence patient preference for fixed combination calcipotriol 50 μg/g (Cal) and betamethasone 0...
August 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28796405/rate-of-serious-infection-in-patients-who-are-prescribed-systemic-biologic-or-nonbiologic-agents-for-psoriasis-a-large-single-center-retrospective-observational-cohort-study
#12
Chantelle Carneiro, Romi Bloom, Erin Ibler, Sara Majewski, Kimberly A Sable, Nicholas J Guido, Jennifer Day, Salvatore Nocadello, Aleksandra G Florek, Dennis P West, Beatrice Nardone
BACKGROUND: Systemic biologic and nonbiologic agents used to treat psoriasis may or may not contribute to serious infection (SI) risk. Safety data, particularly for biologic agents, and associated risk for SI, are scarce. The study's aim was to explore the risk for SI in psoriasis patients exposed to systemic biologic or nonbiologic agents. METHODS: A large, single-center electronic medical record repository was searched between January 2010 and December 2014. Records for patients prescribed a systemic agent for psoriasis (SAP) with psoriasis or psoriatic arthritis diagnoses were included (ICD-9 codes 696...
August 10, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28795763/determinants-of-psychosocial-health-in-psoriatic-patients-a-multi-national-study
#13
Karolina Lesner, Adam Reich, Jacek C Szepietowski, Florence J Dalgard, Uwe Gieler, Lucía Tomas-Aragones, Lars Lien, Françoise Poot, Gregor B Jemec, Laurent Misery, Csanád Szabó, Dennis Linder, Francesca Sampogna, Andrea W M Evers, Jon Anders Halvorsen, Flora Balieva, Andrey Lvov, Servando E Marron, Ilknur K Altunay, Andrew Y Finlay, Sam S Salek, Jörg Kupfer
There are limited data on the differences in the impact of psoriasis between various countries with respect to quality of life (QoL). The aim of this study was to explore the psychosocial health of patients with psoriasis in different European countries. A total of 682 patients were recruited in 13 European countries. All patients completed a questionnaire regarding socio-demographic information, negative life events, suicidal ideation and satisfaction with their dermatologist. Depression and anxiety were assessed with the Hospital Anxiety and Depression Scale (HADS), and QoL with the Dermatology Life Quality Index (DLQI) and EuroQoL (EQ-5D)...
August 10, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28794572/refractory-psoriasis-vulgaris-with-itching-successfully-treated-with-the-anti-interleukin-17a-antibody-secukinumab-a-case-of-secondary-failure-of-other-biologic-agents
#14
Yuko Kurosaki, Kenji Takamori, Yasushi Suga
No abstract text is available yet for this article.
July 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28794555/itolizumab-in-psoriasis
#15
Ankita Srivastava
A number of biologics is being used for the treatment of psoriasis. Itolizumab is one such agent which has been approved in India. It is an anti-CD6 monoclonal antibody that acts by binding to scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. Itolizumab has been found to be safe, with infusion reactions as the most common adverse effect. However, its advantages and disadvantages over other biologicals and immunosuppressants need to be established. Also, its utility in treating other immune-mediated disorders is being explored...
July 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28793154/purpura-annularis-telangiectodes-of-majocchi-associated-with-the-initiation-and-rechallenge-of-apremilast-for-psoriasis-vulgaris
#16
Jaclyn A Kalik, Harvey Friedman, Mark A Bechtel, Alejandro A Gru, Benjamin H Kaffenberger
No abstract text is available yet for this article.
August 9, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28792323/psoriasis-nurse-of-the-year-helped-me-lead-a-normal-life
#17
(no author information available yet)
I have had psoriasis for about 20 years. I can safely say that the care I have received from advanced nurse practitioner Zahira Koreja over the past two years is the best I have ever had. Her care has been instrumental in helping me finally live a normal life by keeping my psoriasis under control.
August 9, 2017: Nursing Standard
https://www.readbyqxmd.com/read/28792259/improvements-in-psoriasis-within-different-body-regions-vary-over-time-following-treatment-with-ixekizumab
#18
Andrew Blauvelt, Talia M Muram, Kyoungah See, Craig H Mallinckrodt, Jeffrey J Crowley, Peter van de Kerkhof
BACKGROUND: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A. OBJECTIVE: Examine the efficacy of ixekizumab in clearing psoriasis within different body regions. METHODS: Data from 3 placebo- (PBO) or PBO- and etanercept (ETN)-controlled trials were integrated. Patients with moderate-to-severe psoriasis were randomized to 12 weeks of PBO (UNCOVER-1, -2, -3, N = 792; UNCOVER-2, -3, N = 361), 50 mg ETN twice weekly (N = 740), or 80 mg ixekizumab every 2 (IXE Q2W; N = 1169; N = 736) or 4 weeks (IXE Q4W; N = 1165; N = 733) after a 160-mg starting dose...
August 9, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28791896/biologics-that-inhibit-the-th17-pathway-and-related-cytokines-to-treat-inflammatory-disorders
#19
Anna Balato, Emanuele Scala, Nicola Balato, Giuseppina Caiazzo, Roberta Di Caprio, Giuseppe Monfrecola, Annunziata Raimondo, Serena Lembo, Fabio Ayala
Advances in the understanding of TNF-α and IL-17 synergistic functions have recently led to the concept that patients who do not respond or who respond inadequately to TNF-α inhibitors may have IL-17-driven diseases, opening up the way for a new class of therapeutic development: Th17-inhibitors. Areas covered: In this review, the authors discuss the central role that the IL-23/Th17 axis plays in the pathogenesis of several inflammatory diseases, such as psoriasis, highlighting its position as a relevant therapeutic target...
August 9, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28790811/retrospective-analysis-to-describe-associations-between-tumor-necrosis-factor-alpha-inhibitors-and-copd-related-hospitalizations
#20
Neil A Accortt, James B Chung, Machaon Bonafede, Brendan L Limone, David M Mannino
BACKGROUND: Limited information exists on the impact of tumor necrosis factor inhibition on COPD exacerbations. This retrospective study characterized this impact among COPD patients with underlying autoimmune conditions, exposed to tumor necrosis factor inhibitors (TNFi) and/or non-biologic disease-modifying antirheumatic drugs (DMARDs). PATIENTS AND METHODS: Adult COPD patients with ≥1 diagnosis for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) before or within 6 months following the index COPD diagnosis were identified from the Truven Health MarketScan(®) databases...
2017: International Journal of Chronic Obstructive Pulmonary Disease
keyword
keyword
43199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"